Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-coun...

FDA Recall #D-0520-2016 — Class III — December 2, 2015

Recall #D-0520-2016 Date: December 2, 2015 Classification: Class III Status: Terminated

Product Description

Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017.

Reason for Recall

Failed Dissolution Specification

Recalling Firm

Pfizer Inc. — New York, NY

Classification

Class III — Not likely to cause adverse health consequences.

Product Type

Drugs

Product Quantity

a) 4005 bottles, b) 104 bottles

Distribution

Nationwide

Code Information

Lot #: C150065; C150064, Exp 6/16

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated